256 related articles for article (PubMed ID: 33731595)
1. Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease.
Walshe M; Borowski K; Boland K; Rho S; Stempak JM; Silverberg MS
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e401-e406. PubMed ID: 33731595
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
Hanžel J; Koželj M; Špes Hlastec A; Kurent T; Sever N; Zdovc J; Smrekar N; Novak G; Štabuc B; Grabnar I; Drobne D
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e831-e836. PubMed ID: 34402470
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
[TBL] [Abstract][Full Text] [Related]
4. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
7. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.
Soufflet N; Boschetti G; Roblin X; Cuercq C; Williet N; Charlois AL; Duclaux-Loras R; Danion P; Mialon A; Faure M; Paul S; Flourie B; Nancey S
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2610-2612. PubMed ID: 30851477
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Ollech JE; Normatov I; Peleg N; Wang J; Patel SA; Rai V; Yi Y; Singer J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT; Pekow J
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):104-110. PubMed ID: 32109634
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan.
Yokoyama S; Asano T; Nagano K; Tsuchiya H; Takagishi M; Tsujioka S; Miura N; Matsumoto T
J Gastroenterol Hepatol; 2021 Nov; 36(11):3069-3076. PubMed ID: 34180096
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
Gonczi L; Szanto K; Farkas K; Molnar T; Szamosi T; Schafer E; Golovics PA; Barkai L; Lontai L; Lovasz B; Juhasz M; Patai A; Sarang K; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Miheller P; Ilias A; Lakatos PL
Dig Liver Dis; 2022 Feb; 54(2):207-213. PubMed ID: 34344576
[TBL] [Abstract][Full Text] [Related]
13. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
14. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
Hanžel J; Zdovc J; Kurent T; Sever N; Javornik K; Tuta K; Koželj M; Smrekar N; Novak G; Štabuc B; Dreesen E; Thomas D; Vovk T; Grabnar I; Drobne D
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):111-118.e10. PubMed ID: 32109630
[TBL] [Abstract][Full Text] [Related]
15. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
16. Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease.
Sollelis E; Quinard RM; Bouguen G; Goutte M; Goutorbe F; Bouvier D; Pereira B; Bommelaer G; Buisson A
World J Gastroenterol; 2019 May; 25(19):2354-2364. PubMed ID: 31148906
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
Thomas PWA; van Caem M; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F;
Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):261-269. PubMed ID: 36708296
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study.
Rowan CR; Keegan D; Byrne K; Cullen G; Mulcahy HE; Sheridan J; Ryan EJ; de Vries A; D'Haens G; Doherty GA
Aliment Pharmacol Ther; 2018 Aug; 48(3):333-339. PubMed ID: 29920697
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.
Plevris N; Fulforth J; Siakavellas S; Robertson A; Hall R; Tyler A; Jenkinson PW; Campbell I; Chuah CS; Kane C; Veryan J; Lam WL; Saunders J; Kelly C; Gaya D; Jafferbhoy H; Macdonald JC; Seenan JP; Mowat C; Naismith G; Potts LF; Sutherland DI; Watts D; Arnott I; Bain G; Jones G; Lees CW
J Gastroenterol Hepatol; 2021 Aug; 36(8):2067-2075. PubMed ID: 33381875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]